How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Pharmaceutical Products Testing Market
- By Test Type: Stability Testing, Microbiological Testing, Chemical Testing, Physical Testing, Bioanalytical Testing
- By Product Type: Active Pharmaceutical Ingredients (API), Finished Dosage Forms, Biologics, Biosimilars, Vaccines
- By Testing Service Provider: Contract Research Organizations (CROs), In-house Testing Laboratories, Third-party Testing Laboratories
- By End User: Pharmaceutical Manufacturers, Biotechnology Companies, Contract Manufacturing Organizations (CMOs), Regulatory Authorities
- By Testing Methodology: In-vitro Testing, In-vivo Testing, Analytical Testing, Genotoxicity Testing, Toxicology Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Stability Testing leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Pharmaceutical Products Testing Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Product Type 5
Testing Service Provider 3
End User 4
Testing Methodology 5
Companies profiled
Eurofins Scientific
SGS SA
Charles River Laboratories International Inc.
Labcorp Drug Development (Covance)
PAREXEL International Corporation
ICON plc
WuXi AppTec
Q2 Solutions
BioReliance (MilliporeSigma)
PPD
Inc. (Thermo Fisher Scientific)
Syneos Health
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →SGS SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PAREXEL International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Q2 Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BioReliance (MilliporeSigma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PPD
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (Thermo Fisher Scientific)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Syneos Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →TÜV SÜD
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Intertek Group plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bureau Veritas
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Medpace Holdings
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,470M by 2033 · 11.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Stability Testing40.6
- Microbiological Testing10.9
- Chemical Testing20.0
- Physical Testing16.7
- Bioanalytical Testing11.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$631.1M → $1,365M · 10.1%
Europe$439.8M → $1,088M · 12.0%
Asia Pacific$401.6M → $957.5M · 11.5%
Latin America$248.6M → $582.8M · 11.2%
Middle East and Africa$191.2M → $412.0M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.152026
11.162027
11.162028
11.182029
11.192030
11.202031
11.232032
11.242033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Eurofins Scientific11.4
- SGS SA26.2
- Charles River Laboratories International Inc.11.4
- Labcorp Drug Development (Covance)9.5
- PAREXEL International Corporation7.1
- ICON plc6.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type11.6%
Product Type33.7%
Testing Service Provider23.6%
End User11.0%
Testing Methodology20.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.0
- Europe24.7
- Asia Pacific21.7
- Latin America13.2
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Eurofins Scientific | 90 | 78 | 98 | 79 | 73 | 86 | 84 |
| SGS SA | 73 | 70 | 70 | 83 | 76 | 83 | 76 |
| Charles River Laboratories International Inc. | 70 | 73 | 62 | 80 | 84 | 76 | 74 |
| Labcorp Drug Development (Covance) | 70 | 61 | 73 | 71 | 78 | 71 | 71 |
| PAREXEL International Corporation | 67 | 64 | 61 | 52 | 55 | 55 | 59 |
| ICON plc | 71 | 54 | 67 | 64 | 71 | 61 | 65 |
| WuXi AppTec | 58 | 55 | 45 | 41 | 41 | 46 | 48 |
| Q2 Solutions | 35 | 41 | 51 | 38 | 43 | 49 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Eurofins Scientific
- SGS SA
- Charles River Laboratories International Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Eurofins Scientific | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| SGS SA | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Charles River Laboratories International Inc. | ◐ | ◐ | − | ◐ | ✓ | ✓ |
| Labcorp Drug Development (Covance) | − | ◐ | ◐ | ◐ | ◐ | − |
| PAREXEL International Corporation | ✓ | ◐ | ✓ | − | ◐ | ◐ |
| ICON plc | ✓ | − | ✓ | ◐ | ◐ | ◐ |
| WuXi AppTec | − | ◐ | ◐ | − | − | − |
| Q2 Solutions | − | ◐ | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Eurofins Scientific84
2SGS SA76
3Charles River Laboratories International Inc.74
4Labcorp Drug Development (Covance)71
5ICON plc65
6PAREXEL International Corporation59
7WuXi AppTec48
8Q2 Solutions43
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Eurofins Scientific
Challenger3
Strong scale, closing on the leaders.
SGS SACharles River Laboratories International Inc.Labcorp Drug Development (Covance)
Contender2
Focused players with pockets of strength.
PAREXEL International CorporationICON plc
Niche2
Specialists in a single segment or region.
WuXi AppTecQ2 Solutions
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Pharmaceutical Products Testing Market — a $506M beachhead inside a $6.93B market.
Beachhead (SOM)$506Mobtainable near-term
Serviceable (SAM)$2.79Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Stability Testing
Best fit — highest urgency & budget in Test Type.
Economic buyer76 fit
Microbiological Testing
Strong fit — clear ROI and a fast path to value.
End user69 fit
Chemical Testing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Testing Service Provider
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel25%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pharmaceutical Products Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation13%
Closed-won5%
$8.3KCAC
$36KLTV
4.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Pharmaceutical Products Testing Market is a durable-growth opportunity — $4.28B by 2033, compounding at 7.6%.
TAM · 2025$2.39Btoday
TAM · 2033$4.28Bforecast
CAGR7.6%2027–2033
Cumulative$29.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.28BTotal addressable market
SAM$1.73BServiceable available market
SOM$368MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.6% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.28BLarge & growingTAM by 2033 at 7.6% CAGR
$1.73BServiceable nowreachable with today’s model
$368MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.34BBear4.9% CAGR
$4.28BBase7.6% CAGR
$5.48BBull10.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Pharmaceutical Products Testing Market — a $2.33B market by 2033. Plan: grow share from 7.3% to 14.8%.
Market size · 2033$2.33Btotal addressable
Market CAGR10.5%2027–2033
Target share14.8%from 7.3% today
Revenue ambition$345Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 14.8% | At risk |
| Revenue | $184M | $345M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 37.5% | 43.6% | Ahead |
| Customer retention | 85.6% | 96.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $40M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Pharmaceutical Products Testing Market conversation — a $5.83B market you can size, segment and defend in minutes.
Market size · 2033$5.83Btotal opportunity
Growth8.5%CAGR to 2033
Addressable buyers1,628+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 2 mopayback period
$79K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Eurofins ScientificSGS SACharles River Laboratories International Inc.Labcorp Drug Development (Covance)PAREXEL International CorporationICON plcWuXi AppTecQ2 Solutions+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pharmaceutical Products Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pharmaceutical Products Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Pharmaceutical Product Information Management System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportPharmaceutical Procurement Platform Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportPharmaceutical Processing And Packaging Equipment Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPharmaceutical Printing Inks Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportPharmaceutical Printing Ink Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportPharmaceutical Printed Carton Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportPharmaceutical Primary Packaging Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPharmaceutical Primary Packaging Lable Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportPharmaceutical Prepacked Chromatography Columns Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportPharmaceutical Pregelatinized Starch Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportPharmaceutical Powder Packaging Machines Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportPharmaceutical Polymer Excipients Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.